Overview | Index | Requesting Use of Contract Resources | DAIDS Home

Currently Funded Resources

The following resources are available to investigators seeking assistance with animal efficacy studies.

• Lentivirus Animal Models

  Animal efficacy models using the following lentiviruses are available for the evaluation of both antiviral and immune-based therapies:

  • HIV
  • SIV (SHIV)
  
  
• OI Animal Models

  Animal models are available for the evaluation of both antimicrobial and immune-based therapies.

• TB Animal Models

  Animal models are available for the evaluation of both antitubercular and immune-based therapies.

• Topical Microbicides

  Vaginal and/or rectal challenge models using nonhuman primates infected with SIV or SHIV are available.

• In Vivo Immunologic Evaluations

  Potential therapies can be evaluated for effects on certain immunologic parameters as a component of the animal efficacy models available for HIV, SIV, and SHIV.

Grant Mechanisms

The following describes grant-based funding opportunities for investigators in the areas of in vivo efficacy evaluations in animal models:

• The NIH Grants and Contracts home page provides links to general information regarding NIH and SBIR/STTR grant mechanisms and to the NIH Guide for Grants and Contracts.

• The NIAID Council News - Extramural Information Center home page provides links to specific programs sponsored by The National Institute of Allergy and Infectious Diseases to which investigators can submit applications.

• The National Cooperative Drug Discovery Group for Opportunistic Infections (NCDDG-OI) grant program supports consortia of academia, industry, and government investigators working collaboratively on targeted discovery and preclinical development of new OI drugs and therapeutic strategies.

  Please contact Dr. Barbara Laughon (phone: 301-402-2304; email: blaughon@niaid.nih.gov for additional information regarding the NCDDG-OI program.

• The Novel HIV Therapies: Integrated Preclinical/Clinical Program (IPCP) supports (1) the discovery and preclinical development of new anti-HIV drugs and therapeutic concepts; and (2) the translation of innovative preclinical findings to the clinic via small clinical studies. This grant program funds consortia of investigators from academia and the private sector, working collaboratively on the development of a defined therapeutic concept identified and proposed by the collaborative group. This mechanism is particularly appropriate for highly experimental therapeutic strategies that are new or otherwise not yet ready for large clinical trials.

  Please contact Dr. Sandra Bridges (phone: 301-496-8197; email: sbridges@niaid.nih.gov for additional information regarding the IPCP.